Multiple Myeloma

Ashraf Badros, MBCHB, discussed new data from the AURIGA study presented at the International Myeloma Society 2024 Annual Meeting, happening September 25 through 29 in Rio de Janeiro, Brazil.

Experts discuss immunotherapy advancements and challenges of resistance, efficacy, and toxicity in patient management.

Minimal residual disease has been a major topic of discussion during the IMS 2024 Annual Meeting.

Promising depth of response and consistent safety profile support the use of talquetamab as a combination agent.

Notably, of the 38 participants who remained on treatment, 37 have switched to less frequent dosing and all have maintained responses.

Experts discuss current knowledge and future indications for immunotherapies and CAR T in early treatment lines.

Artificial intelligence shows promise in improving diagnosis and treatment for patients with multiple myeloma.

Early diagnosis of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) may mitigate progression.

The meeting will focus on the basic, preclinical, and clinical aspects of myeloma, including precursor disease, high-risk disease, immunotherapies, novel biomarkers, and more.

The decision expands treatment options for patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM).

The efficacy and safety profiles of CAR T-cell and bispecific antibody therapies have led to their investigation in earlier lines of therapy, with several new treatments in development.

Researchers suggest prior treatments and follow-up duration may play a larger role.

Breanne Peyton-Thomas, PharmD, BCOP, discusses her work as a pharmacist at Ochsner Health on the CAR T-cell therapy team.

The evolving treatment landscape for multiple myeloma includes debates on the timing and effectiveness of CAR T-cell therapy and quadruple immunotherapy regimens.

Mary McGann, PharmD, BCOP, offers insights into CAR T-cell therapy and the crucial role of pharmacists in mitigating resistance.

Accurate, effective screening is crucial for connecting patients with needed financial resources and support.

Patients can face barriers to BCMA-targeted treatments.

CAR T-cell therapy in multiple myeloma faces challenges from the immunosuppressive cells in the tumor microenvironment.

Kelsea Seago, PharmD, discusses the crucial role of pharmacists in managing chimeric antigen receptor (CAR) T-cell therapy resistance.

Dan Schrum discusses the integral role of pharmacy specialists in translating clinical trial results to clinical practice.

Isatuximab (Sarclisa; Sanofi) in combination with standard-of-care significantly improved progression-free survival in patients with newly diagnosed multiple myeloma.

Dan Schrum highlights the crucial role of lymphodepletion in enhancing the effectiveness of CAR T cell therapy.

CD38 density may indicate the efficacy of monoclonal antibody treatment in patients with multiple myeloma.

The decision is based on positive results from the PERSEUS trial.

Early identification of monoclonal gammopathy of undetermined significance leads to more efficacious disease monitoring and intervention.